Reduced Breast Cancer Risk in Mice with Growth Hormone Antagonist
Author Information
Author(s): Pollak M, Blouin M-J, Zhang J-C, Kopchick J J
Primary Institution: Cancer Prevention Research Unit of the Jewish General Hospital and McGill University
Hypothesis
Does expressing a growth hormone antagonist in transgenic mice reduce mammary gland carcinogenesis?
Conclusion
Transgenic mice expressing a growth hormone antagonist showed lower tumor incidence compared to non-transgenic controls.
Supporting Evidence
- Transgenic mice had lower IGF-I levels and were smaller in size.
- The study suggests a link between body size early in life and breast cancer risk.
Takeaway
Mice that had a special growth hormone blocker got fewer breast tumors, suggesting that body size and hormones might affect cancer risk.
Methodology
Tumor incidence was examined in transgenic mice and non-transgenic littermates after exposure to a carcinogen.
Participant Demographics
Transgenic mice and non-transgenic littermates were used in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website